Market Overview

Goldman Removes Sabre From 'Conviction Buy' List, Sees Few Near-Term Catalysts


Goldman Sachs removed Sabre Corp (NASDAQ: SABR) from its Conviction Buy List on lack of near-term catalysts due to tepid near-term macro conditions and travel datapoints.

However, the brokerage reiterated its Buy rating on Sabre given combination of long-term growth potential and attractive valuation.

"We continue to see significant untapped long-term growth potential for Sabre as we believe its steady growth profile in Travel Network (we see normalized growth of 4% - 6% across macro cycles), combined with secular growth in Solutions (we see 15%+ sustained growth)," analyst James Schneider wrote in a note.

Schneider expects a muted third quarter given geopolitical risk and impact on U.S. airline passenger traffic and overhang on the shares until the appointment of a new CEO, which the company expects at the end of 2016.

Further, the analyst believes Sabre can sustain high-single digit range top line growth and 15 percent plus EPS growth across the cycle.
However, Schneider cut his 2016 EPS view to $1.43 from $1.45 on a customer charge in third quarter.

That said, the analyst maintained his 12-month price target at $37, based on 22X CY17 estimated EPS of $1.70. Schneider feels the valuation is compelling as the stock trades below 9X EV/EBITDA.

At time of writing, shares of Sabre fell 1.29 percent to $27.63. The analyst's $37 price target represents a potential upside of 32 percent.

Latest Ratings for SABR

Jun 2019DowngradesNeutralSell
Jun 2019Initiates Coverage OnBuy
May 2019UpgradesNeutralBuy

View More Analyst Ratings for SABR
View the Latest Analyst Ratings

Posted-In: Goldman Sachs James SchneiderAnalyst Color Reiteration Analyst Ratings


Related Articles (SABR)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

DMD Deal With Summit Is 'Low Risk, High Reward' For Sarepta

Aquinox Pharmaceuticals Surrenders Early Gains